Double Bond Pharmaceutical Reports 5.6-Month Survival Benefit for Temodex in Brain Tumor Study
核心洞察
Double Bond Pharmaceutical's final real-world evidence study of 375 brain tumor patients demonstrates a statistically significant 5.6-month median overall survival advantage for Temodex (搜索) treatment.
The retrospective cohort study showed patients receiving Temodex (搜索) plus standard care achieved 15.6 months median survival versus 10.0 months for standard care alone (p=0.00062).
Temodex (搜索) serves as the technical prototype for SI-053, which has received European Medicines Agency (搜索) Orphan Drug Designation for glioma (搜索) treatment.
Double Bond Pharmaceutical International AB (搜索) has announced final results from its extensive real-world evidence study of Temodex (搜索), demonstrating a statistically significant 5.6-month survival advantage for patients with malignant primary brain tumors (搜索). The retrospective cohort study encompassed 375 patients who underwent surgical resection, with results showing enhanced therapeutic benefit when the local chemotherapy was added to standard surgical workflow.
Study Design and Patient Population
The completed analysis included 124 patients who received Temodex (搜索) in addition to standard of care, compared to 251 patients who received standard of care alone. All patients had undergone surgical resection for malignant primary brain tumors (搜索), with the study designed to evaluate the clinical efficacy of adding local chemotherapy to standardized treatment protocols.
Survival Outcomes and Statistical Significance
The final dataset revealed substantial differences in patient outcomes between treatment groups. Patients receiving Temodex (搜索) achieved a median overall survival of 15.6 months, compared to 10.0 months for the control group receiving standard care alone. This represents an absolute survival benefit of 5.6 months in favor of the Temodex group.
The study demonstrated a hazard ratio of 0.61, with results achieving high statistical significance at p=0.00062. According to Igor Lokot, CEO of Double Bond Pharmaceutical, "An extension of median survival by 5.6 months is an outstanding result for this patient population."
Clinical Development and Regulatory Status
Temodex (搜索) has been used clinically for over a decade in selected regions and serves as the technical prototype for the company's global drug candidate SI-053. SI-053 represents a further developed, locally acting formulation of temozolomide that received Orphan Drug Designation from the European Medicines Agency (搜索) in 2016.
The enhanced reformulation received multiple Competent Authority and Ethics Committee approvals from 2021 to 2023 to initiate Phase 1 clinical studies. In a proof-of-concept study conducted in 2015, SI-053 demonstrated significant overall survival benefit when added to standard care for glioblastoma (搜索) patients.
Scientific Dissemination and Future Presentations
Double Bond Pharmaceutical has submitted a scientific abstract based on these final clinical data to the Society for Neuro-Oncology (搜索) for review ahead of the annual meeting in Philadelphia. The company views this submission as an important step in its international development strategy, with SNO representing the largest multidisciplinary neuro-oncology forum worldwide.
The detailed analysis includes subgroup stratifications based on histological and molecular markers, which have been submitted for presentation at the EANS2026 Congress in Hamburg. Lokot emphasized the importance of disseminating data at these meetings "to ensure maximum international reach and impact for our research findings."
Technology Platform and Future Development
The finalized real-world evidence data establish a verified clinical baseline for the company's technology platform ahead of upcoming prospective clinical trials in Europe. Double Bond Pharmaceutical continues analyzing the dataset using advanced scientific tools to better understand optimal implementation of Temodex (搜索)/SI-053 in standard care protocols.
The company's drug delivery technology, BeloGal®, forms the foundation for its cancer therapy development programs. Beyond SI-053, the company previously received Orphan Drug Designation from the European Medicines Agency (搜索) for SA-033 in treating hepatoblastoma (搜索).